Last reviewed · How we verify
NCT02229344: MOSAIK
Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea
trial testing No Intervention in Colitis, Ulcerative in 368 participants. Completed in 22 February 2022.
22 February 2022
Quick facts
| Lead sponsor | Janssen Korea, Ltd., Korea |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 368 |
| Start date | 1 July 2014 |
| Primary completion | 22 February 2022 |
| Estimated completion | 22 February 2022 |
| Sites | 15 locations across South Korea |
Drugs / interventions tested
- No Intervention
Conditions studied
- Colitis, Ulcerative — all drugs for Colitis, Ulcerative →
Sponsor
Janssen Korea, Ltd., Korea — full company profile →
Who can join
7 and older, any sex, with Colitis, Ulcerative. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to describe clinical course of newly diagnosed moderate to severe ulcerative colitis (chronic inflammatory disease of the colon) in tertiary referral hospitals in Korea for 5-year follow-up under usual care.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea.
Moon JR, Lee CK, Hong SN, Im JP, et al · · 2020 · cited 16× · PMID 31533398 · DOI 10.5009/gnl19107 -
A new opportunity for innovative inflammatory bowel disease research: the moderate-to-severe ulcerative colitis in Korea (MOSAIK) cohort study.
Lee CK, Lee KM, Park DI, Jung SA, et al · · 2019 · cited 13× · PMID 30678443 · DOI 10.5217/ir.2019.00005 -
Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year.
Jo IH, Lee KM, Kim DB, Kim JW, et al · · 2022 · cited 5× · PMID 34373363 · DOI 10.5009/gnl210141 -
Clinical importance of weight gain and associated factors in patients with moderate to severe ulcerative colitis: results from the MOSAIK cohort in Korea.
Yoon H, Park YS, Shin JE, Ye BD, et al · · 2023 · cited 3× · PMID 37990156 · DOI 10.1186/s12876-023-03008-7 -
Anxiety and Depression in Patients with Inflammatory Bowel Diseases: The First Step toward Proper Management.
Lee JW. · · 2020 · cited 2× · PMID 32655016 · DOI 10.5009/gnl20187
Verify or expand the search:
- PubMed search for NCT02229344
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention
Trials testing the same drug.
- NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
- NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
- NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
- NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
- NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
Other recruiting trials for Colitis, Ulcerative
Currently open trials in the same condition.
- NCT07302360 — A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis · recruiting
- NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
- NCT07196748 — A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Col · Phase 3 · recruiting
- NCT07102368 — A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany · recruiting
- NCT06651281 — Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Coli · Phase 3 · recruiting
Other Janssen Korea, Ltd., Korea trials
Trials by the same sponsor.
- NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
- NCT07053345 — A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression · Phase 4 · recruiting
- NCT04852692 — A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants · terminated
- NCT04230252 — A Study of the Newly Formulated Tylenol Tablet (Acetaminophen) to the Tylenol 8 Hour (H) Extended Release (ER) Tablet (A · Phase 1 · completed
- NCT04214691 — A Study of Newly Formulated Tylenol Tablet (Acetaminophen) and Tylenol 8 Hour (H) Extended Release (ER) Tablet (Acetamin · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02229344 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Korea, Ltd., Korea
- Last refreshed: 27 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02229344.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing